Pasithea Therapeutics CORP 8-K filings

Pasithea Therapeutics Corp. announced the appointment of Dr. Kartik Krishnan as Chief Medical Officer, effective May 1, 2026, to lead clinical development for PAS-004.

Pasithea Therapeutics Corp. stockholders approved significant increases in authorized common stock and shares available under its 2023 Stock Incentive Plan.

Pasithea Therapeutics Corp. announced it has regained compliance with Nasdaq's minimum bid price requirement, resolving a previous non-compliance issue.

Pasithea Therapeutics Corp. successfully closed a $60 million public offering, extending its cash runway through at least the first half of 2028.

Pasithea Therapeutics announced positive Phase 1 clinical trial data for its drug candidate PAS-004 across advanced cancer and NF1, alongside a $1 million grant from the ALS Association to study PAS-004 for ALS treatment.

Pasithea Therapeutics announced the activation of a new U.S. clinical trial site at the University of Alabama at Birmingham for its Phase 1/1b study of PAS-004 in adult NF1 patients.

Pasithea Therapeutics Corp. announced revised compensation packages for its executive officers and directors, aiming to align with peer groups and conserve cash.

Pasithea Therapeutics Corp. announced the activation of two clinical trial sites in South Korea for its Phase 1/1b study of PAS-004 in adult neurofibromatosis type 1 patients, with the first patient dosed.

Pasithea Therapeutics Corp. stockholders approved an increase in shares for its incentive plan and granted the board discretion for a reverse stock split.

Pasithea Therapeutics Corp. announced the date for its 2025 annual meeting of stockholders as September 3, 2025, and established deadlines for shareholder proposals and director nominations.

Pasithea Therapeutics Corp. has received a notice from Nasdaq indicating non-compliance with the minimum $1.00 bid price requirement, initiating a 180-day period to regain compliance.

Pasithea Therapeutics Corp. announced an increase in the maximum aggregate offering price of its common stock under its At The Market Offering Agreement, raising it from $2,076,000 to $4,227,000.

Pasithea Therapeutics announces a \$5 million public offering and subsequent closing, with an additional \$1.3 million received from warrant exercises.

Pasithea Therapeutics Corp. has replaced its independent registered public accounting firm, Marcum LLP, with CBIZ CPAs P.C. effective April 23, 2025, following CBIZ's acquisition of Marcum's attest business.

Pasithea Therapeutics Corp. has entered into an agreement to sell up to $2.076 million of its common stock through an at-the-market offering.

Pasithea Therapeutics has announced a $5 million private placement of common stock and warrants, priced at-the-market under Nasdaq rules, to fund working capital and general corporate purposes.

Pasithea Therapeutics reports positive initial safety, tolerability, pharmacokinetic, and preliminary efficacy data from its Phase 1 clinical trial of PAS-004, a novel MEK inhibitor, in advanced cancer patients.

Pasithea Therapeutics Corp. held its 2024 Annual Meeting of Stockholders, where a Class I director was elected and the appointment of Marcum LLP as the independent auditor was ratified.

Pasithea Therapeutics Corp. has scheduled its 2024 annual meeting for June 26, 2024, and set a May 24, 2024 deadline for shareholder proposals.

Pasithea Therapeutics Corp. has successfully regained compliance with Nasdaq's minimum bid price requirement after its stock price remained above $1.00 for a sufficient period.